WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facil...
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included i...
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu, marking a...
